Core Viewpoint - A class action securities lawsuit has been filed against Zenas BioPharma, Inc. due to alleged securities fraud related to its September 2024 initial public offering [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who purchased Zenas BioPharma securities linked to the company's IPO [2]. - The complaint alleges that Zenas BioPharma materially overstated its ability to fund operations with existing cash and expected IPO proceeds, leading to misleading public statements [3]. Group 2: Next Steps for Investors - Investors who suffered losses in Zenas BioPharma have until June 16, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require this [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [5].
Shareholders of Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights – ZBIO